Targeting RAF kinases for cancer therapy: BRAF mutated melanoma and beyond
Explore this paper's citation graph
Summary
This Review describes the development of BRAF inhibitors and the results that have emerged from their analysis in both the laboratory and the clinic and enumerates mechanisms of resistance to BRAF inhibition that have been characterized.
- Type
- review
- Published
- 2014-06-24
- Cited by
- 808
- References
- 158
- Access
- Open access
- OpenAlex
- https://openalex.org/W1985821753
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:34691799
Keywords
Cancer research, Kinase, Cancer, Medicine, Melanoma
References
- Regulation of Raf‐1 activation and signalling by dephosphorylation
- BRAF mutations in metanephric adenoma of the kidney
- KIAA1549‐BRAF Fusions and IDH Mutations Can Coexist in Diffuse Gliomas of Adults
- Drosophila melanogaster homologs of the raf oncogene
- High-throughput tissue microarray analysis of 3p25 (RAF1) and 8p12 (FGFR1) copy number alterations in urinary bladder cancer.
- A minute chromosome in human chronic granulocytic leukemia
- A new oncogene, c-raf, is located on mouse chromosome 6
- High frequency of BRAF mutations in nevi
- B-raf, a new member of the raf family, is activated by DNA rearrangement
- Two unrelated cell‐derived sequences in the genome of avian leukemia and carcinoma inducing retrovirus MH2.
- Inhibition of platelet-derived growth factor- and epidermal growth factor-mediated mitogenesis and signaling in 3T3 cells expressing delta Raf-1:ER, an estradiol-regulated form of Raf-1
- Definition of the human raf amino-terminal regulatory region by deletion mutagenesis
- PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors.
- Oncogene dependent control of miRNA biogenesis and metastatic progression in a model of undifferentiated pleomorphic sarcoma
- Senescence of human fibroblasts induced by oncogenic Raf.
- Dephosphorylation of Ser-259 Regulates Raf-1 Membrane Association*
- p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer
- Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia.
- A Genetic Progression Model of BrafV600E-Induced Intestinal Tumorigenesis Reveals Targets for Therapeutic Intervention
- Vemurafenib: the first drug approved for BRAF-mutant cancer
Cited by
- N-(3-Ethynyl-2,4-difluorophenyl)sulfonamide Derivatives as Selective Raf Inhibitors.
- Phospho-proteomic analyses of B-Raf protein complexes reveal new regulatory principles
- Targeted therapies for advanced non-small cell lung cancer
- Impact of BRAF mutation status in the prognosis of cutaneous melanoma: an area of ongoing research.
- Anomalies moléculaires de la voie MAPK et cancer papillaire de la thyroïde : étude de deux phosphatases spécifiques de ERK, DUSP5 et DUSP6
- Circulating biomarkers in malignant melanoma.
- Induction of Resistance to BRAF Inhibitor Is Associated with the Inability of Spry2 to Inhibit BRAF-V600E Activity in BRAF Mutant Cells
- Activation of the Mitochondrial Fragmentation Protein DRP1 Correlates with BRAFV600E Melanoma
- Synthetic Approaches to Protein Phosphorylation
- Limited Proteolysis Combined with Stable Isotope Labeling Reveals Conformational Changes in Protein (Pseudo)kinases upon Binding Small Molecules.
- Next-generation sequencing reveals rare genomic alterations in aggressive digital papillary adenocarcinoma.
- Comparative Aspects of BRAF Mutations in Canine Cancers
- Alike but Different: RAF Paralogs and Their Signaling Outputs.
- Ferroxitosis: A cell death from modulation of oxidative phosphorylation and PKM2-dependent glycolysis in melanoma
- Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort
- ZEB1: At the crossroads of epithelial-mesenchymal transition, metastasis and therapy resistance
- Melanoma: oncogenic drivers and the immune system.
- Integrated genomic and functional analyses of histone demethylases identify oncogenic KDM2A isoform in breast cancer
- MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road
- Molecular stratification of metastatic melanoma using gene expression profiling : Prediction of survival outcome and benefit from molecular targeted therapy
Related papers
- Abstract 1094: Deciphering driver mechanisms for tumorigenesis in BRAF/NRAS double wild-type melanoma through integration of heterogeneous genome-wide datasets
- Mutation frequency in BRAF and NRAS genes among primary tumors and different types of metastasis from melanoma patients.
- Abstract 3677: Pattern and distribution of BRAF/NRAS and P16CDKN2Amutations among primary an secondary lesions in melanoma patients
- MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients.
- BRAF and NRAS oncogenes and malignant melanoma
- PLA1A expression as a diagnostic marker of BRAF-mutant metastasis in melanoma cancer
- MUTATIONAL STATUS AND SOME CLINICO-MORPHOLOGICAL FEATURES OF CUTANEOUS MELANOMA
- Targeted therapies in melanoma beyond BRAF: targeting NRAS-mutated and KIT-mutated melanoma.
- Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance